Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2022-10-28 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Allergy to resume UK manufacturing production
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a date (28 October 2022) and company information, typical of a regulatory news service announcement. The content discusses a specific operational update (resuming UK manufacturing) and provides an estimated impact on future revenue, which is material information. Since this is a short announcement detailing a specific, material event that doesn't fit neatly into the specific financial report categories (like 10-K, IR, ER), and it is explicitly distributed via RNS (Regulatory News Service), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements. It is not a full report (like 10-K or IR) nor is it solely a dividend notice or management change announcement.
2022-10-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' notification from 'Allergy Therapeutics PLC' dated '19 October 2022'. The form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of a Major Shareholding Notification. The filing type code for this is MRQ.
2022-10-19 English
Allergy Therapeutics – Result of GM
AGM Information Classification · 99% confidence The document is identified by the 'RNS Number' header and contains information about the 'Result of GM' (General Meeting). It confirms that all resolutions were passed and provides details on the subsequent share admission and the resulting total voting rights. This announcement is a formal regulatory disclosure disseminated via the RNS system. Since it reports the outcome of a shareholder vote (the result of the GM), the most specific category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is an RNS filing, DVA is more precise than the general RNS fallback.
2022-10-17 English
UK manufacturing update
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and is clearly distributed via 'RNS, the news service of the London Stock Exchange'. It announces a specific corporate event—a proactive pause in UK manufacturing to optimize quality systems. This type of immediate, material, non-standardized corporate update, especially one flagged as containing 'inside information for the purposes of Article 7 of Regulatory (EU) No596/2014', fits best under the general regulatory announcement category, as it is not a formal financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG/DIRS). Given the source (RNS) and the nature of the announcement, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for general regulatory news releases.
2022-10-04 English
Allergy Therapeutics at Investor Meet Company
Report Publication Announcement Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number: 1929B) on September 29, 2022. The core content announces that company executives will present on the 'Investor Meet Company platform' regarding the 'recently announced Unaudited Preliminary Results for the Year ended 30 June 2022'. This is not the full results report itself (which would likely be an ER or IR), but rather an announcement about a future presentation/webcast event for investors. Since it is an announcement about an upcoming investor event/presentation, it fits best under Investor Presentation (IP) or potentially Report Publication Announcement (RPA) if the focus was solely on the results release date. However, the primary action described is the presentation itself, which is a form of investor communication. Given the options, 'Investor Presentation' (IP) covers the nature of the event being announced (a presentation to investors). Alternatively, because it is a general announcement published through the RNS system about an upcoming event, 'Regulatory Filings' (RNS) is a strong fallback. Since the content is specifically about scheduling an investor presentation/Q&A session, IP is the most specific fit for the *subject matter* being promoted, even though the *format* is an RNS announcement. I will classify it as IP as it details the logistics of an investor presentation.
2022-09-29 English
Subscription and Debt Financing
Share Issue/Capital Change Classification · 99% confidence The document is identified by the header 'RNS Number' and contains the phrase 'Allergy Therapeutics PLC' followed by a date and detailed information about a 'Subscription to Raise £7 million' and 'Issue of Loan Notes to Raise £10 million'. This structure, including the RNS number, the explicit mention of inside information under EU regulation, and the announcement of corporate financing activities (Subscription, Loan Notes, Warrants), strongly indicates a regulatory announcement made via the Regulatory News Service (RNS) system, which is typically used for immediate market disclosure in the UK. Although the document details a financing event (which might suggest 'CAP' - Capital/Financing Update), the primary format and source identifier ('RNS Number') point to the mechanism of dissemination. Furthermore, the document explicitly mentions that the final Circular containing the Notice of General Meeting will be sent to Shareholders and published on the Company's website on or around 29 September 2022, suggesting this announcement serves as the initial regulatory disclosure of the transaction and the upcoming meeting details. Given the options, 'RNS' is the most appropriate code for a general regulatory news service announcement, especially when it details corporate actions like fundraising and sets up a General Meeting, which often requires shareholder approval. Since the document is substantial (47,221 chars) and contains the full details of the transaction rather than just announcing that a report is attached (ruling out RPA based on the 'MENU VS MEAL' rule), and it is a specific regulatory disclosure, RNS is the best fit as a broad regulatory filing category, although CAP is also highly relevant. However, RNS captures the nature of the filing mechanism itself.
2022-09-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.